Long term observational study for multiple sclerosis patients using fingolimod

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Long term observational study for multiple sclerosis patients using fingolimod"

Transcription

1 Investigator: Dr Matthew Jackson (Consultant Neurologist) Centre number: 814 Contact for queries If you have any questions about this study, you can contact: Daytime: Elspeth Wolfenden on Out of hours: Pager No directed to Research Nurse MS unit at the John Radcliffe Wycombe Hospital Queen Alexandra Road High Wycombe Buckinghamshire HP11 2TT Tel: Long term observational study for multiple sclerosis patients using fingolimod You are being invited to take part in an observational study with a medicine, fingolimod (also known as Gilenya), for treating multiple sclerosis. Before you decide whether to take part, you need to understand why the study is being done and what it will involve. This information document is made up of two sections: questions and answers about the study a Consent Form Please take some time to read it carefully, and discuss it with your family, friends and GP if you wish, before making up your mind. If anything in this Information Sheet and Consent Form is not clear, or if you have more questions, please ask the doctor or nurse who gave it to you. About the study: The purpose of this study is to observe patient treatment with fingolimod (Gilenya) or another multiple sclerosis (MS) medication over a period of time to assess long-term safety. The study will record information from patients taking fingolimod (Gilenya) or another MS medication, under the routine medical practice of the clinic/hospital. The study is being organised by Novartis Patient Information and Consent Form, Protocol CFTY720D2406 Page 1 of 9

2 Questions and answers Why have I been invited to take part? Your doctor has diagnosed you with multiple sclerosis (MS) and you may be suitable to take part in this study. You will be starting or have already started taking fingolimod (Gilenya) or another MS medication. There are expected to be approx patients worldwide who take part in this study. Do I have to take part? No it is up to you to decide whether or not you take part. If you do decide to take part, you will be asked to sign the consent form at the back of this document. You will be given a copy of the information sheet and signed consent form to keep. You will still be free to pull out of the study at any time, with or without giving a reason. If you decide to pull out, this will not affect your future treatment and care. Finally, if you decide to take part in the study but lose full mental capacity during the study, your treating doctor may consider keeping you in the study so Novartis can continue to collect medical information on your condition. As you will not be able to agree to continue in the study yourself, your treating doctor/nurse will ask the opinion of a consultee on your behalf. The consultee will be, for example, a legal representative, guardian, relative, carer or friend. The choice of the consultee will be in line with routine hospital/clinic regulations for such cases. If the consultee agrees to provide their opinion they will be given an information sheet, similar to this one, to read and ask questions. If their opinion is you should continue in the study, they will sign a separate consultee declaration form. You will then continue to take part in the study but the consultee is free to pull you out of the study as any time, with or without giving a reason. What will happen to me if I take part? Before you can start the study, your treating doctor and/or nurse will talk to you about the study. If you agree to take part in the study, you will be asked to sign the consent form attached to this leaflet to confirm that you agree to be observed. You will be take part for a minimum of 5 years and a maximum of 8 years depending on when you join the study your treating doctor/nurse will provide you with further information. This is an observational study. This means that your treating doctor and nurse will look after you and treat you following the routine medical practice at the hospital/clinic. This study will not need any additional tests or treatment for your MS to be completed. Novartis will only collect information on your routine tests and visits to the hospital/clinic to treat your MS. You will receive fingolimod (Gilenya) or another MS medication through a hospital prescription by your treating doctor - Novartis will not provide medication to you during the course of your participation. Patient Information and Consent Form, Protocol CFTY720D2406 Page 2 of 9

3 During your routine hospital/clinic visit your treating doctor/nurse will record your care and responses to fingolimod (Gilenya) or other MS medication in your medical file this will include any side effect you have experienced, any other medications you are taking, and other medical test results including but not limited to vital signs, blood sampling, and eye, lung and heart examinations. Novartis has asked your treating doctor/nurse to provide them with the information collected in your medical file during your routine visits. At your first visit for this study you will be asked for information on yourself, your health, MS history and previous MS treatment. In addition, you may receive your first dose of fingolimod (Gilenya) or other MS medication if you have not already started taking it. You will be monitored for any new symptoms (such as; chest pain, dizziness, palpitations, feeling faint, nausea, vomiting), which your treating doctor/nurse will discuss with you fully. During the study, you will visit the clinic/hospital as recommended by your treating doctor/nurse. This is expected to be a minimum of yearly but visits are likely be more often (e.g. every 3 Months in the first year then every 6 Months thereafter) and in line with the hospital routine care. If your treating doctor changes your MS medication while you are taking part in this study, information can still be collected from your routine visits to the hospital/clinic. Your decision to take part in this part of the study is voluntary. You are free to pull out of the study at any time you will not have to provide a reason if you do not wish to. Your MS treatment will continue as normal and will not be affected if you pull out. What will I have to do? The study will follow the routine practice of the hospital/clinic, therefore the treating doctor and nurse will tell you when to visit and what you will have to do. You will be expected to follow what your treating doctor/nurse recommends and this will include, but not be limited to: Attending all hospital/clinic visits as directed. Taking your medication as directed. Telling your doctor/nurse of any other medication you are taking. Telling your doctor/nurse if you feel unwell or have any unusual symptoms, MS related or not, such as a change in your vision, dizziness, fatigue or a slow or irregular heart rate, or breathing difficulties, liver related adverse events, any infection or symptoms of infection such as fever, chills, nausea or vomiting, or changes in your skin. Telling your doctor/nurse immediately if you feel that your MS symptoms are getting worse. If you are a woman who could become pregnant: The use of fingolimod (Gilenya) in women who are or may become pregnant should only be considered if the potential benefit justifies the potential risk to unborn baby. The risks to an unborn baby or a nursing child from fingolimod (Gilenya) are not known. This drug did cause birth defects in the offspring of rats, but it is currently unknown if there is any risk for the development of defects in an unborn baby during the pregnancy in women. Patient Information and Consent Form, Protocol CFTY720D2406 Page 3 of 9

4 If you are a woman of childbearing potential who will newly start on fingolimod (Gilenya), it should be confirmed that you are not pregnant or breast-feeding before entering this study. Your treating doctor/nurse will discuss with you effective measures of birth control to avoid pregnancy during and for 2 months after stopping fingolimod (Gilenya) treatment. Should you become pregnant during the study, your treating doctor/nurse will discuss with you whether or not you should remain on fingolimod (Gilenya) based on the potential benefit and whether it justifies the potential risk to the unborn baby. In addition, your treating doctor/nurse will discuss with you the option of participating in an optional pregnancy registry. The aim of this pregnancy registry is to collect information about pregnancy and birth outcomes in women who have been taking fingolimod (Gilenya) just before or during their pregnancy. Your treating doctor/nurse will give you further details should it be necessary. You should not breast-feed while you are taking fingolimod (Gilenya). Fingolimod (Gilenya) can pass into breast milk and there is a risk of serious side effects for a breast-fed baby. Speak with your treating doctor/nurse before breast-feeding while you take fingolimod (Gilenya). What are the possible benefits of taking part? You will receive no direct benefit from taking part in this observational study information will only be collected on what your treating doctor decides to do under the hospital/clinic routine medical practice. However, your taking part may help to gain knowledge on the long-term effects of fingolimod (Gilenya), which may help patients to get better care for their MS in the future. Who cannot take part in this study? If you have private medical or life insurance Please check with your insurer that it is acceptable under the terms of your policy for you to take part in this study. What are the possible side effects and risks of taking part? This study is observational study based on the routine care and practice of your hospital/clinic. As a result, there are no additional risks to taking part in this study. Like all medicines, fingolimod (Gilenya) can cause side effects, although not everybody gets them. Side effects may occur with certain frequencies, which are defined as follows: Very common: Affects more than 1 in 10 patients Common: Affects between 1 and 10 in every 100 patients Uncommon: Affects between 1 and 10 in every 1,000 patients Very common: Infection from flu virus with symptoms such as tiredness, chills, sore throat, joint or muscles aching, fever Headache Patient Information and Consent Form, Protocol CFTY720D2406 Page 4 of 9

5 Diarrhoea (very loose stool) Back pain Cough Increase levels of a blood test (called Alanine transaminase (ALT)) that can help show liver damage Common: Disease of the lung known as Bronchitis with symptoms such as cough with phlegm, and chest pains Illness of the digestive system and stomach (Gastroenteritis) with symptoms such as vomiting, nausea, diarrhoea, fever Herpes virus infection (shingles or herpes zoster or herpes simplex). Symptoms of herpes zoster may include pain, blisters, numbness of a area. Symptoms of Herpes simplex may include blisters, burning, itching or pain around the mouth or genitals. Slow heartbeat (known bradycardia) A type of abnormal heart rhythm known as atrioventricular block Feeling of pressure and pain in the cheeks and forehead, known as sinusitis Infection from fungi affecting the skin, hair or nails (ringworm) Dizziness Tingling or numbness Migraine (severe headache often accompanied by nausea, vomiting and sensitivity to light) Weakness Itchy, red, burning rash (signs of eczema) Hair loss Itching Weight loss Being short of breath Abnormal liver blood test results that may show damage to the liver Abnormal blood test results that may show damage to body tissues including the liver. Test is for Gamma-glutamyl transferase (GGT). Blood triglyceride (fat) increased Low level of white blood cells (lymphocytes, leucocytes) Depression Eye pain Blurred vision Increase in blood pressure. Uncommon: Some side effects are more uncommon. If you experience any of these, please contact your doctor/nurse straight away: A serious condition of the lung (Pneumonia) with symptoms such as fever, cough, and difficulty breathing Swelling in the back of the eye (Macular oedema) with symptoms such as eye shadows, blind spots and blurred vision, and lack of colour details. Low level of certain white blood cells (neutrophils) Some side effects could be or could become serious. If you experience any side effects tell your treating doctor/nurse immediately. These are not all of the possible side effects of fingolimod (Gilenya) - for more information, please ask your treating doctor or nurse, or refer to the medication leaflet or summary of product characteristics. The other MS medications taken during this study will have their own side effects. For more information, please ask your treating doctor or nurse, or refer to the medication leaflet or summary of product characteristics. Patient Information and Consent Form, Protocol CFTY720D2406 Page 5 of 9

6 What if new information becomes available during the study? Fingolimod is a licensed treatment for multiple sclerosis. If new information becomes available during this observational study your treating doctor/nurse will update you. What if something goes wrong? This is an observational study following the hospital/clinic routine practice. If you are not happy with the general care you receive during the study, please speak first to your treating doctor or nurse, who will try to resolve the problem. He/she should also tell you about the hospital/clinic standard complaints procedure in case you wish to take the matter further. As this is an observational study, cases that may require insurance cover should be referred to and handled by the hospital/clinic. However, should it be required, Novartis has in place product & public liability insurance to support this type of study where treatment and care is provided by the hospital/clinic only. What happens at the end of the study? You will continue to take MS medication as is required by the routine medical care for your MS. About 6 months after the study ends, your doctor will know the results of the study, and can provide you with information should you wish. Any report that is published about the study will not identify you or any other patient taking part. What information about me will be collected? The information (data) collected in the study will include: personal data information that could be used to identify you, such as your initials and date of birth sensitive personal data information about your health and medical history To protect your right to privacy, there are Data Protection Laws in European Union Member States. These laws control: o o o how personal and sensitive personal data (including your biological samples) is collected how it can be used where it can be passed on to When you give this information to someone (known as the data controller) they must comply with Data Protection Laws and only use the data in ways for which you have given permission. The data controller for the study is Novartis Pharma Services AG (the company organising the study). What will the information be used for? The information collected in the study will be used to find out how safe switching the medication is for treating the condition being studied. The data will be retained for at least 15 years. If and when it is disposed of, this will be done securely. Patient Information and Consent Form, Protocol CFTY720D2406 Page 6 of 9

7 The results of the study may be used in presentations or published in scientific reports. Any presentation or published report about the study will not name or otherwise identify you. In future, Novartis may wish to use information from the study for future research into the causes and treatment of the condition being studied. This will not include genetic research unless you have signed a separate consent form. Will my taking part in this study be kept confidential? Your data will be collected Your data will be coded and collected on a paper record / directly into a computer at the hospital / clinic. Your name will not be disclosed outside the hospital / clinic. You have the right to check the accuracy of the data held and correct any errors. Your medical records will be checked To make sure the information collected in the study is accurate, it will need to be checked by researchers and authorised persons working on behalf of Novartis and for government health departments. You are asked to give permission for these authorised people to see your medical records. They will keep the information confidential and your rights to privacy will be protected. With your permission, we will let your GP know You are asked to give permission for us to let your GP know that you are taking part in the study. Your doctor may need to contact your GP to obtain more information about you. Please ask your doctor if you would like a copy of any correspondence. Information may be passed on Information from this study may be passed on to government health departments and related companies in countries within and outside Europe (the European Economic Area), for administering this study and for possible further scientific study. In some of these countries, the data protection laws are not as strict as those within the European Economic Area. The information passed on this way will never include your name. Who is organising and paying for this study? The study is being organised and funded by Novartis Pharma Services AG and is being run by the medical staff in the hospital / clinic. Novartis will make payments into your study doctor s hospital research fund to cover the costs of this study. Has the study been approved? Yes. A Research Ethics Committee has reviewed and approved this research study. The Research Ethics Committee includes healthcare professionals as well as non-medical people. All members of the committee are completely independent from anyone organising the study. Patient Information and Consent Form, Protocol CFTY720D2406 Page 7 of 9

8 Where can I get more information? If you have more questions about this study, you can contact the study doctor whose name and number are on the front page of this Information Sheet and on the Consent Form. What will happen if I don t want to carry on with the study? You are free to withdraw from the study at any time, without giving a reason, and without your medical care or legal rights being affected. If you should decide to leave the study, you should tell the doctor or staff. All data collected up until the date of your withdrawal will be used. You have the right to decide whether data from any assessments after your withdrawal can be used. If you withdraw from the study, researchers, authorised persons from Novartis and the regulatory authorities will still require access to your medical notes to verify the data collected up to the date of your withdrawal. Patient Information and Consent Form, Protocol CFTY720D2406 Page 8 of 9

9 Investigator: Dr Matthew Jackson (Consultant Neurologist) Centre number: 814 Contact for queries If you have any questions about this study, you can contact: Daytime: Elspeth on Out of hours: Tel ask for Neurology Registrar on call. Amersham Hospital Whielden Street Amersham Buckinghamshire HP7 0JD Tel: Long term observational study for multiple sclerosis patients using fingolimod Please initial each box to confirm that you have read, understood and agreed each of the numbered points. 1 I have read and understood this Information Sheet and Consent Form and I have had the time to consider it. I have had the opportunity to ask questions and they have been answered to my satisfaction. 2 I understand that my taking part is voluntary and that I am free to withdraw at any time, without giving any reason, and without my medical care or legal rights being affected and that if I withdraw from the study for any reason, Novartis will use my data up to when I withdraw from the study. 3 I understand that my medical notes may be looked at by authorised persons from Novartis, from the local health authority or from regulatory authorities, where it is relevant to my taking part in this research. I give my permission for these people to have access to my records. I understand that if I withdraw prematurely that my records may need to be accessed after my withdrawal in order to verify data collected while I was in the study. 4 I consent to the collection, use and transfer of personal and sensitive personal data about me, including medical information I understand that Novartis may pass sensitive, personal data, without my name, to regulatory authorities and/or to its subsidiary companies, for administering this study and for future research into the causes and treatment of multiple sclerosis. I understand that these authorities or companies may be in countries within or outside the EEA, and that some of these countries outside the EEA do not have laws regulating the transfer of personal data. I give my permission for such transfer of data. 6 I consent to my GP being told that I am taking part in this study I agree to take part in the above study. 7 When you have initialled all the above boxes, please complete the first box below (including the date) yourself: Name of patient (CAPITALS): Signature: Date: Name of doctor/nurse taking consent (CAPITALS): Signature: Date: Patient number: Patient s initials: Original to be kept in the study Investigator Folder; Second original or a copy of the original to be given to the patient. The Information Sheet and Consent Form are one entire document and must not be separated. Patient Information and Consent Form, Protocol CFTY720D2406 Page 9 of 9

GILENYA Fingolimod hydrochloride

GILENYA Fingolimod hydrochloride GILENYA Fingolimod hydrochloride Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about. It does not contain all the available information. It does

More information

GILENYA Fingolimod hydrochloride Consumer Medicine Information (CMI)

GILENYA Fingolimod hydrochloride Consumer Medicine Information (CMI) GILENYA Fingolimod hydrochloride Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Gilenya. It does not contain all the available information.

More information

Teriflunomide (Aubagio) 14mg once daily tablet

Teriflunomide (Aubagio) 14mg once daily tablet Teriflunomide (Aubagio) 14mg once daily tablet Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Teriflunomide. The decision

More information

Infliximab is used to treat psoriasis, psoriatic arthritis, and several other inflammatory conditions, including other inflammatory skin diseases.

Infliximab is used to treat psoriasis, psoriatic arthritis, and several other inflammatory conditions, including other inflammatory skin diseases. INFLIXIMAB What are the aims of this leaflet? This leaflet has been written to help you understand more about the medication infliximab. It tells you what it is, how it works, how it is used to treat skin

More information

Presenting the SUTENT Patient Call Center.

Presenting the SUTENT Patient Call Center. Presenting the SUTENT Patient Call Center. Please see patient Medication Guide and full prescribing information attached. We re here to support you. Dealing with cancer is a journey. Along the way, you

More information

AUBAGIO Conversation Starter

AUBAGIO Conversation Starter AUBAGIO Conversation Starter When you are choosing a multiple sclerosis (MS) treatment for the first time or are considering switching your MS therapy, there can be a lot to think about for both you and

More information

Multiple sclerosis disease-modifying drugs second line treatments

Multiple sclerosis disease-modifying drugs second line treatments Great Ormond Street Hospital for Children NHS Foundation Trust: Information for Families Multiple sclerosis disease-modifying drugs second line treatments The following information should be read in conjunction

More information

Gilenya. Exceptional healthcare, personally delivered

Gilenya. Exceptional healthcare, personally delivered Gilenya Exceptional healthcare, personally delivered Your Consultant Neurologist has suggested that you may benefit from treatment with Gilenya. The decision to start this form of treatment can be difficult.

More information

Mycophenolate. Dosage and monitoring record for patients with interstitial lung disease

Mycophenolate. Dosage and monitoring record for patients with interstitial lung disease Mycophenolate Dosage and monitoring record for patients with interstitial lung disease This booklet contains information about your immunosuppressant treatment. Keep this booklet with you at all times

More information

RITUXIMAB (Rituxan) Rituximab 2007 Page 1 of 5

RITUXIMAB (Rituxan) Rituximab 2007 Page 1 of 5 RITUXIMAB (Rituxan) Rituximab is FDA approved for the treatment of low-grade or follicular CD20-positive, B-cell non-hodgkin's lymphoma (NHL); treatment of diffuse large B-cell CD20-positive NHL; treatment

More information

Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider:

Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP. Primary Care Provider: Liver Disease & Hepatitis Program Providers: Brian McMahon, MD, Steve Livingston, MD, Lisa Townshend, ANP Primary Care Provider: If you are considering hepatitis C treatment, please read this treatment

More information

MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules. What is the most important information I should know about POMALYST?

MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules. What is the most important information I should know about POMALYST? MEDICATION GUIDE POMALYST (POM-uh-list) (pomalidomide) capsules What is the most important information I should know about POMALYST? Before you begin taking POMALYST, you must read and agree to all of

More information

Facts About Chickenpox and Shingles for Adults

Facts About Chickenpox and Shingles for Adults Facts About Chickenpox and Shingles for Adults What is chickenpox? Chickenpox, also known as varicella, is a very contagious disease caused by the varicella-zoster virus. It is spread easily through the

More information

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients

Oxford University Hospitals. NHS Trust. Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis. Information for patients Oxford University Hospitals NHS Trust Department of Neurology Natalizumab (Tysabri) for Multiple Sclerosis Information for patients page 2 What is Natalizumab and what is it used for? Natalizumab is an

More information

MS Treatments Gilenya

MS Treatments Gilenya 1 MSology Essentials Series Gilenya (fingolimod) Developed by MSology with the invaluable assistance of multiple sclerosis nurse advisors: Trudy Campbell Dalhousie MS Research Unit, Capital Health, Halifax,

More information

Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules

Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules Medication Guide TASIGNA (ta-sig-na) (nilotinib) Capsules Read this Medication Guide before you start taking Tasigna and each time you get a refill. There may be new information. This information does

More information

PATIENT INFORMATION INSURANCE INFORMATION

PATIENT INFORMATION INSURANCE INFORMATION (mm/dd/yyyy): Have you been to Physicians Urgent Care before? Yes No Arrival Time: If yes, when? Is this a follow-up to a previous visit: Yes No PATIENT INFORMATION Patient s First Name: Middle Name: Last

More information

Patient Medication Guide Brochure

Patient Medication Guide Brochure Patient Medication Guide Brochure 1 MEDICATION GUIDE TASIGNA (ta-sig-na) (nilotinib) Capsules Read this Medication Guide before you start taking TASIGNA and each time you get a refill. There may be new

More information

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa)

MEDICATION GUIDE. PROCRIT (PRO KRIT) (epoetin alfa) MEDICATION GUIDE PROCRIT (PROKRIT) (epoetin alfa) Read this Medication Guide: before you start PROCRIT. if you are told by your healthcare provider that there is new information about PROCRIT. if you are

More information

People who are likely to have swine flu may be offered antiviral medicines.

People who are likely to have swine flu may be offered antiviral medicines. Patient information from the BMJ Group Swine flu There's been a lot of concern about the spread of swine flu, a new strain of flu virus that emerged in 2009. However, there are treatments that can help

More information

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and

MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and MEDICATION GUIDE REMICADE (Rem-eh-kaid) (infliximab) Read the Medication Guide that comes with REMICADE before you receive the first treatment, and before each time you get a treatment of REMICADE. This

More information

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth.

Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T. Patient s first names. Date of birth. Patient identifier/label: Page 1 of 6 PATIENT AGREEMENT TO SYSTEMIC THERAPY: CONSENT FORM FEC-T Patient s surname/family name Patient s first names Date of birth Hospital Name: Guy s Hospital St. Thomas

More information

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide

What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide For Patients What You Need to Know About LEMTRADA (alemtuzumab) Treatment: A Patient Guide Patients: Your doctor or nurse will go over this patient guide with you. It is important to ask any questions

More information

Ear Infections Chickenpox chickenpox

Ear Infections Chickenpox chickenpox Ear Chickenpox Infections chickenpox Chickenpox Chickenpox is a common, very contagious viral infection that over 90% of people get during childhood unless they have been immunised. After an infection,

More information

Patient Information Leaflet: Part 1 select-d

Patient Information Leaflet: Part 1 select-d Patient Information Leaflet: Part 1 select-d Anticoagulation Therapy in SELECTeD Cancer Patients at Risk of Recurrence of Venous Thromboembolism Introduction This

More information

Information for you. Chickenpox and pregnancy. About this information. What is chickenpox? What are the symptoms of chickenpox?

Information for you. Chickenpox and pregnancy. About this information. What is chickenpox? What are the symptoms of chickenpox? Information for you Published in June 2015 (next review date: 2018) Chickenpox and pregnancy About this information This information is for you if you want to know more about chickenpox and pregnancy.

More information

MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate

MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate MEDICATION GUIDE mitoxantrone (mito-xan-trone) for injection concentrate Read this Medication Guide before you start receiving mitoxantrone and each time you receive mitoxantrone. There may be new information.

More information

For the Patient: Cetuximab Injection Other names: ERBITUX

For the Patient: Cetuximab Injection Other names: ERBITUX Traditional Chinese For the Patient: Cetuximab Injection Other names: ERBITUX Cetuximab (se tux i mab) is a drug that is used to treat some types of cancer. It is a monoclonal antibody, a type of protein

More information

Paclitaxel and Carboplatin

Paclitaxel and Carboplatin PATIENT EDUCATION patienteducation.osumc.edu What is Paclitaxel (pak-li-tax-el) and how does it work? Paclitaxel is a chemotherapy drug known as an anti-microtubule inhibitor. Another name for this drug

More information

TCH: Docetaxel, Carboplatin and Trastuzumab

TCH: Docetaxel, Carboplatin and Trastuzumab PATIENT EDUCATION patienteducation.osumc.edu TCH: Docetaxel, Carboplatin and Trastuzumab What is TCH? It is the short name for the drugs used for this chemotherapy treatment. The three drugs you will receive

More information

TC: Docetaxel and Cyclophosphamide

TC: Docetaxel and Cyclophosphamide PATIENT EDUCATION patienteducation.osumc.edu What is TC? It is the short name for the drugs used for this chemotherapy treatment. The two drugs you will receive during this treatment are Docetaxel (Taxotere

More information

Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab

Package leaflet: Information for the patient. Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab Package leaflet: Information for the patient Entyvio 300 mg powder for concentrate for solution for infusion vedolizumab This medicine is subject to additional monitoring. This will allow quick identification

More information

If you have any concerns about being given this vaccine, ask your doctor or pharmacist.

If you have any concerns about being given this vaccine, ask your doctor or pharmacist. PNEUMOVAX 23 Pneumococcal Vaccine Single Dose Vial/Pre-filled Syringe What is in this leaflet This leaflet answers some common questions about PNEUMOVAX 23. It does not contain all the available information.

More information

Bayer Receives FDA Approval for BETACONNECT First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment

Bayer Receives FDA Approval for BETACONNECT First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment News Release Intended for U.S. Media Only Bayer Receives FDA Approval for BETACONNECT First and Only Electronic Autoinjector in Relapsing-Remitting Multiple Sclerosis (RRMS) Treatment Whippany, N.J., September

More information

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included.

1. Study title Is the title self explanatory to a layperson? If not, a simplified title should be included. These guidelines apply to all research projects where human subjects are involved in the study GUIDELINES FOR RESEARCHERS PATIENT INFORMATION SHEET & CONSENT FORM The guidance, which follows, applies primarily

More information

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose.

It is important that you tell your family and the people closest to you of this increased sensitivity to opioids and the risk of overdose. MEDICATION GUIDE VIVITROL (viv-i-trol) (naltrexone for extended-release injectable suspension) Read this Medication Guide before you start receiving VIVITROL injections and each time you receive an injection.

More information

Roswell Ear, Nose, Throat, & Allergy 342 W. Sherrill Lane Suite A, Roswell, New Mexico 88201 (575)-622-2911 Fax: (575)-622-2598

Roswell Ear, Nose, Throat, & Allergy 342 W. Sherrill Lane Suite A, Roswell, New Mexico 88201 (575)-622-2911 Fax: (575)-622-2598 Roswell Ear, Nose, Throat, & Allergy 342 W. Sherrill Lane Suite A, Roswell, New Mexico 88201 (575)-622-2911 Fax: (575)-622-2598 Patient Registration Form: (Please Print all Pertinent Information) Last

More information

READ THIS LEAFLET VERY CAREFULLY, AND KEEP IT IN A SAFE PLACE. FLU IS SPREADING IN IRELAND, AND THIS INFORMATION IS IMPORTANT FOR YOU AND YOUR FAMILY.

READ THIS LEAFLET VERY CAREFULLY, AND KEEP IT IN A SAFE PLACE. FLU IS SPREADING IN IRELAND, AND THIS INFORMATION IS IMPORTANT FOR YOU AND YOUR FAMILY. READ THIS LEAFLET VERY CAREFULLY, AND KEEP IT IN A SAFE PLACE. FLU IS SPREADING IN IRELAND, AND THIS INFORMATION IS IMPORTANT FOR YOU AND YOUR FAMILY. Information and medical advice for the public on Pandemic

More information

The flu vaccination for the winter of 2012/13. Who should have it, and why. Includes information for pregnant women

The flu vaccination for the winter of 2012/13. Who should have it, and why. Includes information for pregnant women The flu vaccination for the winter of 2012/13 Who should have it, and why Includes information for pregnant women Introduction This leaflet explains how you can protect yourself against flu this coming

More information

Gemcitabine and Cisplatin

Gemcitabine and Cisplatin PATIENT EDUCATION patienteducation.osumc.edu What is Gemcitabine (jem-site-a been)? Gemcitabine is a chemotherapy medicine known as an anti-metabolite. Another name for this drug is Gemzar. This drug is

More information

The flu vaccination. Winter 2013/14. Who should have it and why. Includes information for pregnant women

The flu vaccination. Winter 2013/14. Who should have it and why. Includes information for pregnant women The flu vaccination Winter 2013/14 Who should have it and why Includes information for pregnant women Introduction This leaflet explains how you can protect yourself against flu this coming winter, and

More information

INFLUENZA (FLU) Flu and You

INFLUENZA (FLU) Flu and You Influenza (Flu) What is the flu? The flu is an illness caused by flu viruses. The flu may make people cough and have a sore throat and fever. They may also have a runny or stuffy nose, feel tired, have

More information

JAMES PETROS, M.D., INC. PHONE: (408) 528-8833 FAX: (408) 528-8557

JAMES PETROS, M.D., INC. PHONE: (408) 528-8833 FAX: (408) 528-8557 FIGHTING PAIN. TOUCHING LIVES. JAMES PETROS, M.D., INC. PHONE: (408) 528-8833 FAX: (408) 528-8557 Personal Information Emergency Contact Today s Date: Name: Patient: Realtionship: Birth Date: Age: Sex:

More information

MEDICATION GUIDE STELARA

MEDICATION GUIDE STELARA MEDICATION GUIDE STELARA (stel ar a) (ustekinumab) Injection What is the most important information I should know about STELARA? STELARA is a medicine that affects your immune system. STELARA can increase

More information

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets

Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Patient Information VYTORIN (VI-tor-in) (ezetimibe and simvastatin) Tablets Read this Patient Information carefully before you start taking VYTORIN and each time you get a refill. There may be new information.

More information

Leflunomide Leflunomide

Leflunomide Leflunomide Drug information Leflunomide Leflunomide This leaflet provides information on leflunomide and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets

More information

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab)

Patient Guide. Important information for patients starting therapy with LEMTRADA (alemtuzumab) Patient Guide Important information for patients starting therapy with LEMTRADA (alemtuzumab) This medicinal product is subject to additional monitoring. This will allow quick identification of new safety

More information

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT PROVERA (A PROGESTIN HORMONE)?

WHAT IS THE MOST IMPORTANT INFORMATION I SHOULD KNOW ABOUT PROVERA (A PROGESTIN HORMONE)? PATIENT INFORMATION PROVERA (medroxyprogesterone acetate tablets, USP) Read this PATIENT INFORMATION before you start taking PROVERA and read the patient information each time you refill your PROVERA prescription.

More information

Chickenpox in pregnancy: what you need to know

Chickenpox in pregnancy: what you need to know Chickenpox in pregnancy: what you need to know Published December 2003 Contents Page number Key points 1 About this information 2 What is chickenpox? 2 What should I do if I come into contact with chickenpox?

More information

Application For Admission To The Non-Surgical Spinal Decompression Program At The Spinal Decompression Center of Long Beach

Application For Admission To The Non-Surgical Spinal Decompression Program At The Spinal Decompression Center of Long Beach Application For Admission To The Non-Surgical Spinal Decompression Program At The Spinal Decompression Center of Long Beach If you are reading this form, you have qualified for a consultation with Dr.

More information

Early Access to Medicines Scheme Treatment protocol Information for patients

Early Access to Medicines Scheme Treatment protocol Information for patients Early Access to Medicines Scheme Treatment protocol Information for patients Introduction The aim of the Early Access to Medicines Scheme (EAMS) is to provide earlier availability of promising new unlicensed

More information

Tuberculosis and You A Guide to Tuberculosis Treatment and Services

Tuberculosis and You A Guide to Tuberculosis Treatment and Services Tuberculosis and You A Guide to Tuberculosis Treatment and Services Tuberculosis (TB) is a serious disease that can damage the lungs or other parts of the body like the brain, kidneys or spine. There are

More information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la]

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION. [new-ka la] READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE PATIENT MEDICATION INFORMATION Pr NUCALA [new-ka la] mepolizumab lyophilized powder for subcutaneous injection Read this carefully before you start

More information

2 What you need to know before you have Ampiclox

2 What you need to know before you have Ampiclox Reason for update: GDS 14 & QRD Updates Response to questions for variation update section 4.1 of SPC MHRA Submission Date: 6 November 2014 MHRA Approval Date: Text Date: October 2014 Text Issue and Draft

More information

Staying on Track with TUBERCULOSIS. Medicine

Staying on Track with TUBERCULOSIS. Medicine Staying on Track with TB TUBERCULOSIS Medicine What s Inside: Read this brochure to learn about TB and what you can do to get healthy. Put it in a familiar place to pull out and read when you have questions.

More information

BE SURE. BE SAFE. VACCINATE.

BE SURE. BE SAFE. VACCINATE. DON T GET OR GIVE THE FLU THIS YEAR THANK YOU Vaccination is the only protection. www.immunisation.ie BE SURE. BE SAFE. VACCINATE. FLU VACCINE 2013-2014 Healthcare workers prevent the spread of flu and

More information

St. Luke s MS Center New Patient Questionnaire. Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor?

St. Luke s MS Center New Patient Questionnaire. Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor? St. Luke s MS Center New Patient Questionnaire Name: Date: Birth date: Right or Left handed? Who is your Primary Doctor? Who referred you to the MS Center? List any other doctors you see: Reason you have

More information

MEDICATION GUIDE SYLATRON (SY-LA-TRON) (Peginterferon alfa-2b)

MEDICATION GUIDE SYLATRON (SY-LA-TRON) (Peginterferon alfa-2b) MEDICATION GUIDE SYLATRON (SY-LA-TRON) (Peginterferon alfa-2b) Read this Medication Guide before you start taking SYLATRON, and each time you get a refill. There may be new information. This Medication

More information

Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules

Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules Medication Guide EQUETRO (ē-kwĕ-trō) (carbamazepine) Extended-Release Capsules Read this Medication Guide before you start taking EQUETRO and each time you get a refill. There may be new information. This

More information

ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE)

ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) ORAL ANTICOAGULANTS RIVAROXABAN (XARELTO) FOR PULMONARY EMBOLISM (PE) Information Leaflet Your Health. Our Priority. Page 2 of 6 What Are Anticoagulants And What Do They Do? This information leaflet has

More information

AVONEX. What is Avonex?

AVONEX. What is Avonex? AVONEX What is Avonex? Avonex is the brand name for a disease modifying treatment for people with MS. The active ingredient is interferon beta 1a, which comes in a solution or powder, and is given by injection.

More information

LOEWENBERG SCHOOL OF NURSING LOEWENBERG SCHOOL OF NURSING HEALTH EXAMINATION FORM (FORM 003)

LOEWENBERG SCHOOL OF NURSING LOEWENBERG SCHOOL OF NURSING HEALTH EXAMINATION FORM (FORM 003) SECTION I: To be completed by STUDENT: Name: DOB: Address: Phone (H): Phone (C): Health History: Please complete the following information: Recent weight loss or gain Fatigue, fever, sweats Difficulty

More information

atovaquone and proguanil

atovaquone and proguanil atovaquone and proguanil Pronunciation: a TOE va kwone and pro GWAHN il Brand: Malarone, Malarone Pediatric What is the most important information I should know about atovaquone and proguanil? You should

More information

Rituximab. Drug information Rituximab. This leaflet provides information on rituximab and will answer any questions you have about the treatment.

Rituximab. Drug information Rituximab. This leaflet provides information on rituximab and will answer any questions you have about the treatment. Drug information Rituximab Rituximab This leaflet provides information on rituximab and will answer any questions you have about the treatment. Arthritis Research UK produce and print our booklets entirely

More information

Pradaxa Introduction for New Users

Pradaxa Introduction for New Users Pradaxa Introduction for New Users Introduction Blood clots frequently happen in people who have diseases of the blood vessels or heart. They may pose a dangerous threat to some people. Blood clots may

More information

Temozolomide (oral) with concurrent radiotherapy to the brain

Temozolomide (oral) with concurrent radiotherapy to the brain Temozolomide (oral) with concurrent radiotherapy to the brain Temozolomide (oral) with concurrent radiotherapy to the brain This leaflet is offered as a guide to you and your family. You will find it useful

More information

Your NHL Journey. RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) Indications. Important Safety Information

Your NHL Journey. RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) Indications. Important Safety Information * Your NHL Journey RITUXAN for Follicular Lymphoma and Diffuse Large B-cell Lymphoma (DLBCL) * Non-Hodgkin s Lymphoma Indications RITUXAN (rituximab) is indicated for the treatment of: Follicular CD20-positive

More information

Cortisol - contains the active ingredient hydrocortisone

Cortisol - contains the active ingredient hydrocortisone Cortisol - contains the active ingredient hydrocortisone Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about Cortisol. It does not contain all of the

More information

Southwest General Surgical Associates General & Vascular Surgery 8230 Walnut Hill Lane Suite 408 Dallas, TX 75231 Phone-214)369-5432 Fax-214)369-5591

Southwest General Surgical Associates General & Vascular Surgery 8230 Walnut Hill Lane Suite 408 Dallas, TX 75231 Phone-214)369-5432 Fax-214)369-5591 Southwest General Surgical Associates General & Vascular Surgery 8230 Walnut Hill Lane Suite 408 Dallas, TX 75231 Phone-214)369-5432 Fax-214)369-5591 Andres U. Katz, M.D. Richard S. Anderson, M.D. G. Thomas

More information

Chickenpox in pregnancy: what you need to know

Chickenpox in pregnancy: what you need to know Chickenpox in pregnancy: what you need to know First published December 2003 Revised edition published November 2008 What is chickenpox? Chickenpox is a very infectious illness caused by a virus called

More information

IMPORTANT: PLEASE READ

IMPORTANT: PLEASE READ PART III: CONSUMER INFORMATION combined hepatitis A (inactivated) and hepatitis B (recombinant) vaccine This leaflet is part III of a three-part "Product Monograph" published when was approved for sale

More information

Breast Cancer. Breast Cancer Page 1

Breast Cancer. Breast Cancer Page 1 Breast Cancer Summary Breast cancers which are detected early are curable by local treatments. The initial surgery will give the most information about the cancer; such as size or whether the glands (or

More information

Neuro-Opthamalogy. USF Eye Institute and Ear, Nose and Throat Center. Dear Neuro-ophthalmology Patients:

Neuro-Opthamalogy. USF Eye Institute and Ear, Nose and Throat Center. Dear Neuro-ophthalmology Patients: USF Eye Institute and Ear, Nose and Throat Center Neuro-Opthamalogy Dear Neuro-ophthalmology Patients: The following information is to prepare you for your visit with Dr. Drucker. If you have had an MRI,

More information

Medical History Form

Medical History Form Medical History Form 1800 N. Main Street Wheaton, IL 60187 630.614960 Fax: 630.683727 rmg.nm.org/homecare Name: ; Birth date: / / ; Date: / / Person filling out form: ; Relationship: Thank you for taking

More information

Adalimumab Drug information. Adalimumab is used for several types of inflammatory arthritis.

Adalimumab Drug information. Adalimumab is used for several types of inflammatory arthritis. Adalimumab Drug information Adalimumab is used for several types of inflammatory arthritis. Adalimumab should effectively treat your condition, and stop it causing damage to your joints. It has been tested

More information

Frequently asked questions about whooping cough (pertussis)

Frequently asked questions about whooping cough (pertussis) Frequently asked questions about whooping cough (pertussis) About whooping cough What is whooping cough? Whooping cough is a highly contagious illness caused by bacteria. It mainly affects the respiratory

More information

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen 250mg Tablets PHENOXYMETHYLPENICILLIN

PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen 250mg Tablets PHENOXYMETHYLPENICILLIN PACKAGE LEAFLET: INFORMATION FOR THE PATIENT Kopen 250mg Tablets PHENOXYMETHYLPENICILLIN Read all of this leaflet carefully before you start taking this medicine because it contains important information

More information

For the Patient: Dasatinib Other names: SPRYCEL

For the Patient: Dasatinib Other names: SPRYCEL For the Patient: Dasatinib Other names: SPRYCEL Dasatinib (da sa' ti nib) is a drug that is used to treat many types of cancer. It is a tablet that you take by mouth. Tell your doctor if you have ever

More information

Copayment Is Due At Time Of Visit. Self-pay (payment due at time of service)

Copayment Is Due At Time Of Visit. Self-pay (payment due at time of service) REGISTRATION FORM Please present your insurance card and photo ID at time of check-in. Settlement of patient financial responsibility is expected at time of service. Copayment Is Due At Time Of Visit.

More information

Clinical Trials Network

Clinical Trials Network National Drug Abuse Treatment Clinical Trials Network STOP SMOKING STUDY Should I Join? NATIONAL INSTITUTES OF HEALTH U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Introduction Many people who abuse drugs

More information

What FLUCLOXACILLIN is used for and how it works

What FLUCLOXACILLIN is used for and how it works FLUCLOXACILLIN Flucloxacillin, as the sodium salt What is in this leaflet This leaflet answers some common questions about FLUCLOXACILLIN. It does not contain all the information available on this medicine.

More information

AC: Doxorubicin and Cyclophosphamide

AC: Doxorubicin and Cyclophosphamide PATIENT EDUCATION patienteducation.osumc.edu What is AC? It is the short name for the drugs used for this chemotherapy treatment. The two drugs you will receive during this treatment are Doxorubicin (Adriamycin

More information

WELCOME TO TRI-COUNTY EYE CLINIC

WELCOME TO TRI-COUNTY EYE CLINIC WELCOME TO TRI-COUNTY EYE CLINIC Thank you for choosing Tri-County Eye Clinic as the provider for your eye care. You have an appointment at one of the following two locations: 15122 Dedeaux Road, Gulfport,

More information

MEDICATION GUIDE Prolia (PRÓ-lee-a) (denosumab) Injection, for subcutaneous use

MEDICATION GUIDE Prolia (PRÓ-lee-a) (denosumab) Injection, for subcutaneous use MEDICATION GUIDE Prolia (PRÓ-lee-a) (denosumab) Injection, for subcutaneous use Read the Medication Guide that comes with Prolia before you start taking it and each time you get a refill. There may be

More information

What is the most important information I should know about TREXIMET?

What is the most important information I should know about TREXIMET? PATIENT IMPORTANT SAFETY INFORMATION What is the most important information I should know about TREXIMET? TREXIMET may increase your chance of a heart attack or stroke that can lead to death. TREXIMET

More information

PATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN

PATIENT INFORMATION LEAFLET. CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN PATIENT INFORMATION LEAFLET CEFALEXIN 250 mg AND 500 mg CAPSULES CEFALEXIN Read all of this leaflet carefully before you start taking this medicine. - Keep this leaflet. You may need to read it again.

More information

Pregnant? There are many ways to help protect you and your baby. Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella)

Pregnant? There are many ways to help protect you and your baby. Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella) Pregnant? There are many ways to help protect you and your baby Immunise against: Flu (Influenza) Whooping cough (Pertussis) German measles (Rubella) mmunisation This leaflet describes the vaccinations

More information

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS,

WARNING, CONTRAINDICATIONS, WARNINGS AND PRECAUTIONS, FACT SHEET BRANDED/GENERIC NAME: ABRAXANE for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) ABRAXANE is an albumin-bound form of paclitaxel with a

More information

Type 2 diabetes Definition

Type 2 diabetes Definition Type 2 diabetes Definition Type 2 diabetes is a lifelong (chronic) disease in which there are high levels of sugar (glucose) in the blood. Type 2 diabetes is the most common form of diabetes. Causes Diabetes

More information

Get the Facts About. Disease

Get the Facts About. Disease Get the Facts About TB TUBERCULOSIS Disease What s Inside: 3 PAGE Get the facts, then get the cure 4 PAGE 9 PAGE 12 PAGE Learn how TB is spread Treatment for TB disease Talking to family and friends about

More information

DOXYLAMINE. Please read this leaflet and the packaging of the medicine you have purchased carefully before you start using doxylamine.

DOXYLAMINE. Please read this leaflet and the packaging of the medicine you have purchased carefully before you start using doxylamine. What is in this leaflet DOXYLAMINE New Zealand Consumer Medicine Information The medicine you have purchased contains doxylamine. This leaflet is intended to provide information on the active ingredient

More information

Be cancer aware. Patient Information

Be cancer aware. Patient Information Be cancer aware Patient Information Author ID: AMK Leaflet Number: CC 041 Version: 1 Name of Leaflet: Be cancer aware Date Produced: November 2015 Review Date: November 2017 Be cancer aware Page 1 of 11

More information

Chemotherapy Side Effects Worksheet

Chemotherapy Side Effects Worksheet Page 1 of 6 Chemotherapy Side Effects Worksheet Medicines or drugs that destroy cancer cells are called cancer chemotherapy. It is sometimes the first choice for treating many cancers. Chemotherapy differs

More information

For the Patient: Paclitaxel injection Other names: TAXOL

For the Patient: Paclitaxel injection Other names: TAXOL For the Patient: Paclitaxel injection Other names: TAXOL Paclitaxel (pak'' li tax' el) is a drug that is used to treat many types of cancer. It is a clear liquid that is injected into a vein. Tell your

More information

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours

Vincristine by short infusion Doxorubicin by injection Cyclophosphamide by injection Rituximab by an infusion over between 60 minutes to a few hours R-CHOP R-CHOP This leaflet is offered as a guide to you and your family. The possible benefits of treatment vary; for some people chemotherapy may reduce the risk of the cancer coming back, for others

More information

Valaciclovir generichealth Treatment of zoster and herpes labialis

Valaciclovir generichealth Treatment of zoster and herpes labialis CONSUMER MEDICINE INFORMATION Valaciclovir generichealth Treatment of zoster and herpes labialis contains the active ingredient valaciclovir (hydrochloride) What is in this leaflet This leaflet answers

More information

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU

Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU FOR MS RELAPSES Stepping toward a different treatment option LEARN WHAT ACTHAR CAN DO FOR YOU As a person with multiple sclerosis (MS), you know firsthand the profound impact MS relapses can have on your

More information

Is ISENTRESS right for you?

Is ISENTRESS right for you? Is ISENTRESS right for you? Models ISENTRESS.com Provided as an educational resource by Merck INDICATION ISENTRESS is a prescription HIV-1 medicine used with other antiretroviral medicines to treat human

More information

MEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets

MEDICATION GUIDE ACTOPLUS MET (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets MEDICATION GUIDE (ak-tō-plus-met) (pioglitazone hydrochloride and metformin hydrochloride) tablets Read this Medication Guide carefully before you start taking and each time you get a refill. There may

More information

Which injectable medication should I take for relapsing-remitting multiple sclerosis?

Which injectable medication should I take for relapsing-remitting multiple sclerosis? Which injectable medication should I take for relapsing-remitting multiple sclerosis? A decision aid to discuss options with your doctor This decision aid is for you if you: Have multiple sclerosis Have

More information